- Biogen dumps dubious Alzheimer’s drug after profit-killing FDA scandal https://arstechnica.com/science/2024/01/biogen-dumps-dubious-alzheimers-drug-after-profit-killing-fda-scandal/ 2 comments health
Linking pages
- The right bacteria turn farms into carbon sinks | Ars Technica https://arstechnica.com/science/2024/02/the-right-bacteria-turn-farms-into-carbon-sinks/ 33 comments
- $158,000 ALS drug pulled from market after failing in large clinical trial | Ars Technica https://arstechnica.com/science/2024/04/158000-als-drug-pulled-from-market-after-failing-in-large-clinical-trial/ 22 comments
Linked pages
- The right bacteria turn farms into carbon sinks | Ars Technica https://arstechnica.com/science/2024/02/the-right-bacteria-turn-farms-into-carbon-sinks/ 33 comments
- House investigation faults FDA, Biogen for Alzheimer’s drug approval - The Washington Post https://www.washingtonpost.com/science/2022/12/29/alzheimers-fda-biogen-aduhelm/ 7 comments
Related searches:
Search whole site: site:arstechnica.com
Search title: Biogen dumps dubious Alzheimer’s drug after profit-killing FDA scandal | Ars Technica
See how to search.